文献速递类风湿关节炎

阿巴西普作为类风湿关节炎首个生物制剂不增加严重感染风险:基于人群的队列研究

Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study.
PubMed 文献 · Semin Arthritis Rheum · 2019-01-25

该研究基于美国Truven MarketScan与Supplemental US Medicare数据库(2007–2014年),纳入5,752例首次使用阿巴西普和78,556例首次使用其他生物制剂DMARD的类风湿关节炎患者,比较严重感染住院风险。结果显示阿巴西普总体严重感染风险与其他生物制剂DMARD相比无显著差异(HR 1.04,95%CI 0.89–1.21),且风险不随用药时长或感染部位而变化。

要点

  • 阿巴西普作为首个生物制剂不增加总体严重感染风险(HR 1.04,95%CI 0.89–1.21)。
  • 用药不足1年(HR 1.03,95%CI 0.87–1.22)和超过1年(HR 1.08,95%CI 0.77–1.52)风险均未增加。
  • 骨关节、胃肠道、呼吸道、皮肤软组织及泌尿道等部位特异性感染风险亦未升高。

核心结论

  • 阿巴西普作为类风湿关节炎首个生物制剂DMARD,与其他生物制剂DMARD相比,严重感染风险无显著差异。

研究设计与样本

  • 基于美国Truven MarketScan和Supplemental US Medicare(2007–2014年)的基于人群的队列研究,纳入5,752例首次使用阿巴西普和78,556例首次使用其他生物制剂DMARD的患者。
  • 采用Cox比例风险模型,在控制年龄和倾向性评分十分位后,估计严重感染住院的调整风险比(HR)及95%置信区间(CI)。

主要发现

  • 阿巴西普组193例发生严重感染,其他生物制剂DMARD组1,531例,粗发病率分别为4.45/100人年和3.62/100人年。
  • 与其它生物制剂DMARD相比,阿巴西普总体严重感染风险无显著增加(HR 1.04,95%CI 0.89–1.21)。
  • 风险不随用药时长变化:不足1年HR 1.03(95%CI 0.87–1.22),超过1年HR 1.08(95%CI 0.77–1.52)。
  • 部位特异性感染(骨关节、胃肠道、呼吸道、皮肤软组织、泌尿道)风险亦未增加。

关键数值与推荐

  • 主要结局为需住院治疗的严重感染,包括骨关节、胃肠道、呼吸道、皮肤软组织和泌尿道感染。

临床怎么用

  • 在类风湿关节炎患者中,选择阿巴西普作为首个生物制剂DMARD时,严重感染风险与其他生物制剂DMARD相当,可作为临床决策参考。

局限性

  • 研究为观察性设计,可能存在残余混杂;数据来源于美国行政索赔数据库,感染诊断依赖编码准确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether abatacept as initial biologic disease-modifying antirheumatic drug (DMARD) in the treatment of rheumatoid arthritis is associated with an increased risk of serious infections, including bone and joint, gastrointestinal, respiratory tract, skin and soft tissue, and urinary tract, when compared with other biologic DMARDs. METHODS: We performed a population-based cohort study among patients newly-treated with biologic DMARDs within the US-based Truven MarketScan® population and Supplemental US Medicare from 2007 to 2014. Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of serious infections requiring hospitalisation associated with initiation of abatacept, compared with initiation of other bDMARDs, after controlling for age and deciles of the propensity score. RESULTS: The cohort included 5,752 patients who initiated abatacept and 78,556 who initiated another biologic DMARD, of whom 193 and 1531 had a serious infection during follow-up (crude incidence rate 4.45 per 100 person-years and 3.62 per 100 person-years, respectively). Compared with other biologic DMARDs, the use of abatacept was not associated with an increased incidence of serious infections overall (HR 1.04, 95% CI 0.89-1.21). The risk did not vary by duration of use (<1 year: HR 1.03, 95% CI 0.87-1.22; >1 year: HR 1.08, 95% CI 0.77-1.52). In addition, the risk was not increased for the site-specific infections. CONCLUSION: The use of abatacept as first biologic DMARD in the treatment of rheumatoid arthritis was not associated with different risks of serious infections compared with other biologic DMARDs.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Montastruc F, Renoux C, Hudson M, et al. Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study. Semin Arthritis Rheum. 2019. PMID: 30772001. doi:10.1016/j.semarthrit.2019.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。